Characteristics of cardiac toxicity after definitive radiation therapy for thoracic esophageal cancer in Japanese patients
Journal of Radiation Research · 2025
DOI: 10.1093/jrr/rraf056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiation Research, 2025. Verfasst von Keita Tsukahara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, International Medical Center, Saitama Medical University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. Hauptthemen laut MEDLINE: Cardiotoxicity, Esophageal Neoplasms, Radiation Injuries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In recent years, there has been growing interest in cardiac toxicity following radiation therapy (RT) for esophageal cancer; however, detailed incidence and risk factors in Japanese patients remain unclear. The purpose of this study was to clarify the incidence, timing, risk factors, and dose-volume relationships of multiple cardiac toxicities, including pericardial effusion, heart failure, arrhythmia, cardiac valve disease and acute coronary syndrome. We retrospectively analyzed patients of thoracic esophageal cancer without distant metastasis who were treated with curative RT at our hospital between 2007 and 2020. Cardiac toxicity events were graded according to common terminology criteria for adverse events v5.0. Association between cardiac dose-volume parameters and grade 2 or higher toxicity was analyzed using logistic regression analysis. The analysis included 250 patients, with a median follow-up period of 21 months. The 2-year cumulative incidence of grade 2 or higher pericardial effusion, heart failure, arrhythmia, and acute coronary syndrome were 36.6%, 0.4%, 1.4%, and 1.3%, respectively. Logistic regression analysis identified the volume of the whole heart receiving 30Gy as a significant risk factor for grade 2 pericardial effusion (OR, 1.03; 95% confidence interval [CI], 1.01–1.04; P < 0.01) and grade 2 arrhythmia (OR, 1.10; 95%CI, 1.02–1.18; P = 0.01). We reported detailed profile of cardiac toxicity in Japanese patients who received curative RT for esophageal cancer. Reducing cardiac radiation dose may reduce the risk of pericardial effusion and arrhythmia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, International Medical Center, Saitama Medical University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan.
- Department of Gastroenterological Surgery, International Medical Center, Saitama Medical University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan.
ORCID-Profile: Keita Tsukahara, Takanori Abe, Tomomi Aoshika, Yu Kumazaki, Shin-Ei Noda, Shingo Kato
Zitieren
APA
Tsukahara, K., Abe, T., Saito, S., Sakaguchi, T., Watanabe, J., Iino, M., Aoshika, T., Ryuno, Y., Michimata, G., Ohta, T., Igari, M., Hirai, R., Kumazaki, Y., Noda, S. E., Kato, S., Miyawaki, Y., & Sato, H. (2025). Characteristics of cardiac toxicity after definitive radiation therapy for thoracic esophageal cancer in Japanese patients. Journal of Radiation Research. https://doi.org/10.1093/jrr/rraf056
Vancouver
Tsukahara K, Abe T, Saito S, Sakaguchi T, Watanabe J, Iino M, et al. Characteristics of cardiac toxicity after definitive radiation therapy for thoracic esophageal cancer in Japanese patients. Journal of Radiation Research. 2025. doi:10.1093/jrr/rraf056
BibTeX
@article{Tsukahara2025,
author = {Tsukahara, Keita and Abe, Takanori and Saito, Satoshi and Sakaguchi, Takumi and Watanabe, Jun and Iino, Misaki and Aoshika, Tomomi and Ryuno, Yasuhiro and Michimata, Genta and Ohta, Tomohiro and Igari, Mitsunobu and Hirai, Ryuta and Kumazaki, Yu and Noda, Shin-Ei and Kato, Shingo and Miyawaki, Yutaka and Sato, Hiroshi},
title = {Characteristics of cardiac toxicity after definitive radiation therapy for thoracic esophageal cancer in Japanese patients},
journal = {Journal of Radiation Research},
year = {2025},
doi = {10.1093/jrr/rraf056}
}
EUVIMED